Clinical Trials are medical research involving human subjects. Clinical Trials evaluate medical, surgical, or behavioral interventions to determine if a novel treatment is safe and effective. There are four phases of Clinical Trial testing used to test the new treatment, determine the most effective dosage, and ensure the adverse effects do not outweigh the medical benefits.
Richard Hughes: New immunogenicity strategies to meet the needs of a developing pandemic Shortly after the COVID-19 pandemic began, the subject of serological testing for anti-viral antibodi...
Learning Objectives: 1. Understanding the integral value of collaboration for advancement in scientific research; how to establish and grow academic, Pharma, and industry connections 2. Lear...
In Pacific Northwest watersheds several species of Pacific salmonid fishes are hosts for the rhabdovirus infectious hematopoietic necrosis virus (IHNV). In this multi-host ecosystem speciali...
Epidemics are occurring at an increasing pace and scale. Our laboratory group has developed platform technologies for discovery of broad and potent neutralizing antibodies for many emerging...
Most currently used conventional influenza vaccines are based on 1940s technology. Advances in immunogen design and vaccine delivery emerging over the last decade open novel opportunities fo...
While the frequency of pandemic threats seems to be increasing, we fortunately have new tools and technologies to make vaccines with more precision and speed and that support a more proactiv...
Advances in genomics and molecular biomarker testing have led to tremendous improvements, ushering in a new era of personalized medicine especially in the oncology practice. Many of these bi...
Seasonal and pandemic influenza virus infections can cause significant disease worldwide. Current vaccines only provide limited, short-lived protection, and antigenic drift/shift in the hema...
SARS-CoV-2 has created significant challenges for laboratories, requiring the development, validation, and scale up of testing in a very short time period--often this was done for multiple m...
FECHA: 19 de Agosto, 2020 HORA: 10:00 AM PST 1:00 PM CST Desde que se detectó por primera vez en Wuhan, China, en 2019, el nuevo coronavirus SARS-CoV-2 y la enfermedad que causa, COVI...
DATA: 19 de agosto, 2020 Horário: às 15:00 horas Desde que foi detectado pela primeira vez em Wuhan, China, em 2019, o novo coronavírus SARS-CoV-2 e a doença que...
B7-H3 is actively being explored as an immunotherapy target for pediatric patients with solid tumors using monoclonal antibodies or T cells expressing chimeric antigen receptors (CARs). B7-H...
DATE: July 23, 2020 TIME: 10:00 am PDT The SARS-CoV-2 pandemic has taken a toll on many sectors of the medical community. As the pandemic took a grip on the laboratory, the need for diagnost...
DATE: July 8, 2020 TIME: 10:00 am PDT This seminar reviews clinical utility of adopting rapid IDH1/2 testing in both hematological and solid tumors and describes the adjusted workflow develo...
Cytokine storm is suspected of producing the overzealous immune response driving the severe cardiopulmonary complications that fuel high morbidity and mortality rates in certain COVID-19 inf...
DATE: June 30, 2020 TIME: 10:00 am PDT, 1:00 pm EDT COVID-19 is a highly pathogenic disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We have assembled a panel...
The 2020 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to rage. While PCR-based assays are used for viral diagnosis, high through-put, rapid s...
Coronavirus disease 2019 (Covid-19) is a global pandemic that has impacted the lives of the entire world’s population. Accurate and effective testing mechanisms to identify those with...
Cancer vaccines are increasingly being developed and tested as a cancer treatment and prevention strategy. Designing cancer vaccines is complicated by a number factors including choice of an...
NCI estimates that cancer will be the leading cause of death in 2030, worldwide. Checkpoint inhibitors and adoptive cell therapies (ACTs) cost up to ~$2 million/patient and have shown durabl...
Background: Acute myeloid leukemia (AML) is a molecularly and clinically heterogeneous hematological malignancy. Despite recent advancements in the treatment of AML, approximately 50% of pat...
Personalized medicine has beomce a paradigm in lung cancer management; ~ 25–30% of advanced lung cancer patients could benefit from a targeted therapy. Several guidelines currently end...
Background: CDK4/6 inhibitors increase tumor immunogenicity in preclinical models of breast cancer and several trials combining CDK4/6 inhibitors and anti-PD1/PDL1 therapies are underway. Ho...
The evolution of clinical trial design in oncology reflects the current clinical paradigm of personalized medicine, weighing both histology and molecularly-defined biomarkers as the pillars...
Richard Hughes: New immunogenicity strategies to meet the needs of a developing pandemic Shortly after the COVID-19 pandemic began, the subject of serological testing for anti-viral antibodi...
Learning Objectives: 1. Understanding the integral value of collaboration for advancement in scientific research; how to establish and grow academic, Pharma, and industry connections 2. Lear...
In Pacific Northwest watersheds several species of Pacific salmonid fishes are hosts for the rhabdovirus infectious hematopoietic necrosis virus (IHNV). In this multi-host ecosystem speciali...
Epidemics are occurring at an increasing pace and scale. Our laboratory group has developed platform technologies for discovery of broad and potent neutralizing antibodies for many emerging...
Most currently used conventional influenza vaccines are based on 1940s technology. Advances in immunogen design and vaccine delivery emerging over the last decade open novel opportunities fo...
While the frequency of pandemic threats seems to be increasing, we fortunately have new tools and technologies to make vaccines with more precision and speed and that support a more proactiv...
Advances in genomics and molecular biomarker testing have led to tremendous improvements, ushering in a new era of personalized medicine especially in the oncology practice. Many of these bi...
Seasonal and pandemic influenza virus infections can cause significant disease worldwide. Current vaccines only provide limited, short-lived protection, and antigenic drift/shift in the hema...
SARS-CoV-2 has created significant challenges for laboratories, requiring the development, validation, and scale up of testing in a very short time period--often this was done for multiple m...
FECHA: 19 de Agosto, 2020 HORA: 10:00 AM PST 1:00 PM CST Desde que se detectó por primera vez en Wuhan, China, en 2019, el nuevo coronavirus SARS-CoV-2 y la enfermedad que causa, COVI...
DATA: 19 de agosto, 2020 Horário: às 15:00 horas Desde que foi detectado pela primeira vez em Wuhan, China, em 2019, o novo coronavírus SARS-CoV-2 e a doença que...
B7-H3 is actively being explored as an immunotherapy target for pediatric patients with solid tumors using monoclonal antibodies or T cells expressing chimeric antigen receptors (CARs). B7-H...
DATE: July 23, 2020 TIME: 10:00 am PDT The SARS-CoV-2 pandemic has taken a toll on many sectors of the medical community. As the pandemic took a grip on the laboratory, the need for diagnost...
DATE: July 8, 2020 TIME: 10:00 am PDT This seminar reviews clinical utility of adopting rapid IDH1/2 testing in both hematological and solid tumors and describes the adjusted workflow develo...
Cytokine storm is suspected of producing the overzealous immune response driving the severe cardiopulmonary complications that fuel high morbidity and mortality rates in certain COVID-19 inf...
DATE: June 30, 2020 TIME: 10:00 am PDT, 1:00 pm EDT COVID-19 is a highly pathogenic disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We have assembled a panel...
The 2020 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to rage. While PCR-based assays are used for viral diagnosis, high through-put, rapid s...
Coronavirus disease 2019 (Covid-19) is a global pandemic that has impacted the lives of the entire world’s population. Accurate and effective testing mechanisms to identify those with...
Cancer vaccines are increasingly being developed and tested as a cancer treatment and prevention strategy. Designing cancer vaccines is complicated by a number factors including choice of an...
NCI estimates that cancer will be the leading cause of death in 2030, worldwide. Checkpoint inhibitors and adoptive cell therapies (ACTs) cost up to ~$2 million/patient and have shown durabl...
Background: Acute myeloid leukemia (AML) is a molecularly and clinically heterogeneous hematological malignancy. Despite recent advancements in the treatment of AML, approximately 50% of pat...
Personalized medicine has beomce a paradigm in lung cancer management; ~ 25–30% of advanced lung cancer patients could benefit from a targeted therapy. Several guidelines currently end...
Background: CDK4/6 inhibitors increase tumor immunogenicity in preclinical models of breast cancer and several trials combining CDK4/6 inhibitors and anti-PD1/PDL1 therapies are underway. Ho...
The evolution of clinical trial design in oncology reflects the current clinical paradigm of personalized medicine, weighing both histology and molecularly-defined biomarkers as the pillars...
Opens in a new windowOpens an external siteOpens an external site in a new window
Follow
